Compare WVE & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | PTY |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2015 | N/A |
| Metric | WVE | PTY |
|---|---|---|
| Price | $15.74 | $12.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $29.94 | N/A |
| AVG Volume (30 Days) | ★ 13.7M | 550.4K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,230,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 103.75 | N/A |
| 52 Week Low | $5.28 | $11.92 |
| 52 Week High | $21.73 | $14.88 |
| Indicator | WVE | PTY |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 40.73 |
| Support Level | $15.23 | $12.77 |
| Resistance Level | $18.50 | $12.95 |
| Average True Range (ATR) | 1.18 | 0.08 |
| MACD | -0.34 | 0.03 |
| Stochastic Oscillator | 16.51 | 67.25 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.